Bioventus Inc. BVS
Set alert
13.15 USD -0.17 -1.31%
At close
10.79 -2.36 -17.98%
Pre-market · Nov 3, 7:28 AM ET
13.07 Day range 13.73
6.47 52-week range 15.89
- YTD
- +76.75%
- 1 year
- +100.46%
- Open
- 13.52
- Prev close
- 13.33
- Mkt cap
- 898.21M
- Vol
- 681.38K
- Avg vol
- 555.03K
- EPS
- 0.78
- P/E
- 16.86
- Div yield
- 0.00%
More statistics
- Low
- 13.07
- High
- 13.73
- Forward P/E
- 16.16
- Beta
- 0.64
- Short ratio
- 7.53
- Inst. own
- 84.85%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 13.72
- 200-d avg
- 10.84
- 1y target
- 17.60
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 17.60 +33.8% upside
Now 13.15
- Target (low)
- 15.00
- Target (mean)
- 17.60
- Target (high)
- 19.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 5
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.16 | 0.13 – 0.18 | 0.15 | +6.7% | 149.52M | +7.8% | 5 |
| Next quarter | 0.25 | 0.23 – 0.28 | 0.24 | +4.2% | 169.96M | +7.6% | 5 |
| Current year | 0.778 | 0.77 – 0.79 | 0.68 | +14.4% | 604.78M | +6.5% | 5 |
| Next year | 0.92 | 0.88 – 0.96 | 0.778 | +18.3% | 645.57M | +6.7% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 17, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 17, 2026 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |
| Jun 30, 2026 | Barrington Research | Maintained | Outperform | Outperform |
| Jun 16, 2026 | Canaccord Genuity | Maintained | Buy | Buy |
| May 22, 2026 | Barrington Research | Maintained | Outperform | Outperform |
| Mar 6, 2026 | Barrington Research | Maintained | Outperform | Outperform |
| Mar 6, 2026 | Craig-Hallum | Maintained | Buy | Buy |
| Feb 9, 2026 | Barrington Research | Initiated | — | Outperform |
| Jul 7, 2025 | Cantor Fitzgerald | Initiated | — | Overweight |
| Mar 17, 2025 | Canaccord Genuity | Maintained | Buy | Buy |
| Dec 17, 2024 | JP Morgan | Upgrade | Underweight | Neutral |
| Nov 6, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Sep 27, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Aug 13, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Aug 7, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| May 8, 2024 | Canaccord Genuity | Maintained | Buy | Buy |
| Mar 13, 2024 | Craig-Hallum | Maintained | Buy | Buy |
| Dec 7, 2023 | Canaccord Genuity | Upgrade | Hold | Buy |
| Apr 3, 2023 | Craig-Hallum | Maintained | — | Hold |
| Nov 30, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Nov 22, 2022 | Craig-Hallum | Downgrade | Buy | Hold |
| Nov 10, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Nov 9, 2022 | Canaccord Genuity | Downgrade | Buy | Hold |
| Nov 9, 2022 | JP Morgan | Downgrade | Overweight | Underweight |
| Oct 11, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Sep 7, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Aug 12, 2022 | Morgan Stanley | Maintained | — | Overweight |
| May 12, 2022 | Morgan Stanley | Maintained | — | Overweight |
| Mar 21, 2022 | Goldman Sachs | Maintained | — | Neutral |
| Mar 15, 2022 | Craig-Hallum | Initiated | — | Buy |